Prosecution Insights
Last updated: October 04, 2026

Regulus Therapeutics Inc.

1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Regulus Therapeutics Inc. currently manages 1 pending office action. This matter is assigned to VANHORN, ABIGAIL LOUISE, who serves as the busiest examiner for the portfolio. The concentration of work under 1 distinct examiner suggests a focused prosecution effort for the company at this stage.

The presence of a single pending action indicates a low volume of active disputes or new filings requiring immediate response. Because the busiest examiner handles the entire workload, the company's current prosecution strategy depends on the specific tendencies of this individual. This limited workload simplifies the management of the company's intellectual property interests.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

0
Life Sciences
0% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
100% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
VANHORN, ABIGAIL LOUISE 1 46.8% +22.4%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18693783 Methods and Compositions for Avoiding Off-Target Effects VANHORN, ABIGAIL LOUISE —

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18693783 Methods and Compositions for Avoiding Off-Target Effects VANHORN, ABIGAIL LOUISE — §102§103DP Non-Final OA — Pending Mar 20, 2024

Managing Regulus Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month